Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022.

Joshua G Petrie Jennifer P KingDavid L McClureMelissa A R RolfesJennifer K MeeceDavid PattinsonGabriele NeumannYoshihiro KawaokaEdward A BelongiaHuong Q McLean

Published in: Influenza and other respiratory viruses (2023)

An mRNA vaccine booster dose added significant protection against SARS-CoV-2 infection, but protection decreased over time. A second booster did not add significant protection for adults ≥50 years of age. Uptake of recommended bivalent boosters should be encouraged to increase protection against Omicron BA.4/BA.5 sublineages.

Keyphrases

coronavirus disease
sars cov
randomized controlled trial
respiratory syndrome coronavirus
systematic review
binding protein